Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Now Rated "Buy" by Wall Street Brokerages

Key Points

• Telix Pharmaceuticals has a consensus “Buy” rating from six analysts: four buys, one strong buy and one hold. The average 12-month price target is $20.50, well above the reported share price of $11.45.
• Recent broker actions were generally positive, including Wedbush’s $22 price target, HC Wainwright’s $20 target and RBC’s upgrade to “moderate buy.”
• Institutional interest increased, with several funds raising their positions, while Telix shares remained above their one-year low of $6.28 but below the $13.11 high.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $20.50.

A number of brokerages have recently issued reports on TLX. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, September 23rd. Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Friday. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, September 21st.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of TLX. Lazard Asset Management LLC boosted its stake in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000. Private Advisor Group LLC lifted its position in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after acquiring an additional 128,070 shares during the period. XY Capital Ltd grew its stake in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company's stock valued at $822,000 after purchasing an additional 58,739 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after purchasing an additional 8,423 shares during the period.

Telix Pharmaceuticals Price Performance

Shares of Telix Pharmaceuticals stock opened at $11.45 on Monday. The company has a 50-day simple moving average of $11.35 and a two-hundred day simple moving average of $10.50. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.